A Phase 4 interventional study of Fulvestrant in Locally Advanced or and Metastatic Breast Cancer, sponsored by AstraZeneca. Completed at 9 sites in Korea, Republic of. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-09-05.
Sponsored by AstraZeneca · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.
Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 45th largest by enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2015, is one of 4 in phase 4, and was the 52nd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19–80 · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
University of California, Irvine · Sites in United States
Ages 18+
Prof. Wolfgang Janni · Sites in Germany, Switzerland
Ages 18+ · Women only
Royal Marsden NHS Foundation Trust · Sites in France, United Kingdom
Ages 18+
By country, each count listing its studies:
Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 130 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, fulvestrant is the treatment under test here. Read study by study →
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 63 · Phase 3 21 · Phase 4 4
First in 1997; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 71 across the 94 interventional studies. Of the 55 that completed or were terminated, 34 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 95 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 82nd largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2015, is one of 7 in phase 4, and was the 108th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
7 of the studies testing fulvestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT07163481Hunan Cancer HospitalA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | 2026-12 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT00585507Beth Israel Deaconess Medical CenterEfficacy and Safety of 500mg of Fulvestrant | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 95 studies testing fulvestrant in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single-arm study aims to assess the safety and tolerability profile of Fulvestrant(Faslodex®) as 2nd line and later therapy in postmenopausal women with locally advanced or metastatic breast cancer. The primary objective is to evaluate the adverse events after Fulvestrant (Faslodex®) for about 6 months
This study is a Phase 4, single-arm, safety and tolerability study of fulvestrant (Faslodex®) as 2nd line therapy in postmenopausal women with locally advanced or metastatic breast cancer.
All of enrolled patients in this study will be injected fulvestrant (Faslodex®). This study will be performed for about 3 years and approximately 100 patients(actual target will be 80 treated patients) will be enrolled in about 10 investigational sites.
After obtaining the written informed consent from the patients, the information of demographic and medical history will be collected and laboratory tests will be performed.
Patients who meet the inclusion/exclusion criteria will be injected the fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection. The information of adverse events will be collected after the 1st dose of IP injection. In case that the evaluation of tumor response might be performed in regular clinical practice, those data will also be collected as well. The quality of life will also be measured.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Faslodex treated in the study
Drug: Fulvestrant
fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.
Safety(Percentage of Participants With Adverse Events and/or Adverse Drug Reactions)
Percentage of patients with AEs.
Time frame: Adverse events were collected from treatment initiation to end of the study about 6 months for each patient.
First subject enrolled: 29MAY2015 Last subject last visit: 06MAY2016 This study was conducted from 29 May 2015 to 06 May 2016 and 85 subjects from 9 study centres participated.
| Milestone | Single Arm |
|---|---|
| Started | 83 |
| Completed | 82 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Percentage of patients with AEs.
| Percentage of participants | Single Arm |
|---|---|
| Adverse Events(AE) | 81.5 (71.3 to 89.3) |
| ADR; based on current South Korea label. | 38.3 (27.7 to 49.7) |
| Serious AE | 11.1 (5.2 to 20.1) |
| Serious ADR | 0 (0 to 4.4) |
| Unexpected AE | 71.6 (60.5 to 81.1) |
| Unexpected ADR | 24.7 (15.8 to 35.5) |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Arm | — | 9/81 (11.1%) | 66/81 (81.5%) |
| Event | Single Arm |
|---|---|
| CHOLANGITISHepatobiliary disorders | 1/81 |
| contusion of brainInjury, poisoning and procedural complications | 1/81 |
| HydronephrosisRenal and urinary disorders | 1/81 |
| Blood creatinine increasedInvestigations | 1/81 |
| Acute lymphocytic leukaemia (in remission)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/81 |
| Joint DislocationInjury, poisoning and procedural complications | 1/81 |
| Bone PainMusculoskeletal and connective tissue disorders | 1/81 |
| pelvic painReproductive system and breast disorders | 1/81 |
| Event | Single Arm |
|---|---|
| nauseaGastrointestinal disorders | 10/81 |
| MyalgiaMusculoskeletal and connective tissue disorders | 10/81 |
| back painGeneral disorders | 9/81 |
| dizzinessNervous system disorders | 9/81 |
| ConstipationGastrointestinal disorders | 7/81 |
| headacheNervous system disorders | 7/81 |
| PainGeneral disorders | 6/81 |
| AnorexiaGastrointestinal disorders | 6/81 |
| arthralgiaMusculoskeletal and connective tissue disorders | 6/81 |
| upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 6/81 |
In this study, a total of 85 subjects were enrolled, and 83 of them received study drug open labelled, single arm. The safety population included 81 subjects who met all of the inclusion/exclusion criteria, and 74 of them were included in the efficacy population.
| Age, Continuous(years) | Single Arm |
|---|---|
| Age | 56.6 ± 9.34 |
| Sex: Female, Male(Participants) | Single Arm |
|---|---|
| Female | 81 |
| Male | 0 |
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Ran from May 2015 to primary completion in May 2016, 11 months.
Results were first posted in Mar 2018, 1 year 10 months after primary completion.
Of 130 phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fulvestrant